XML 30 R46.htm IDEA: XBRL DOCUMENT v2.4.0.8
Commitments and Contingencies (Details) (USD $)
3 Months Ended 12 Months Ended 0 Months Ended 1 Months Ended 12 Months Ended 0 Months Ended
Sep. 30, 2012
Jun. 30, 2013
Jun. 30, 2012
Jun. 30, 2011
Jul. 27, 2007
830 Winter Street, Waltham, MA
item
sqft
Apr. 30, 2012
830 Winter Street, Waltham, MA
sqft
Dec. 31, 2009
830 Winter Street, Waltham, MA
sqft
Jul. 31, 2007
830 Winter Street, Waltham, MA
Jul. 27, 2007
830 Winter Street, Waltham, MA
Maximum
Jun. 30, 2013
Norwood, MA
Apr. 30, 2013
100 River Ridge Drive, Norwood, MA
sqft
Operating leases                      
Area of space leased (in square feet)         89,000 7,310         7,507
Initial lease term period         12 years 3 years         5 years 2 months
Number of additional terms for which lease agreement can be extended         2            
Additional term period for which lease agreement can be extended         5 years         5 years 5 years
Area of property covered under sublease agreement (in square feet)             14,100        
Additional period for which sublease agreement can be extended             2 years        
Construction allowance received                 $ 13,300,000    
Leasehold improvements recorded under construction allowance         12,000,000            
Receipts from the landlord towards leasehold improvements               10,800,000      
Facilities rent expense, net of sublease income   4,800,000 4,800,000 4,600,000              
Minimum rental commitments under the non-cancelable operating lease agreements                      
2013   6,636,000                  
2014   6,780,000                  
2015   6,549,000                  
2016   6,624,000                  
2017   6,831,000                  
Thereafter   10,029,000                  
Total minimum lease payments   43,449,000                  
Total minimum rental payments from subleases   (1,088,000)                  
Total minimum lease payments, net   42,361,000                  
Collaborations                      
Potential future success-based milestone and third-party payments cancelled under license agreement with Janssen Biotech 41,000,000                    
Maximum amount payable in the future under the Company's current collaborative agreements   2,000,000                  
Amount reimbursable by a third party   $ 1,400,000